<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
While Humana Inc.’s (NYSE:HUM) stock already seems to price in the near-term concerns around rebounding medical costs and high COVID-19 costs, it offers an opportunity to gain exposure to “the post-COVID accelerating growth environment and associated 2022 inflection,” according to SVB Leerink. The Humana Analyst: Whit Mayo initiated coverage of Humana with an Outperform rating and a price target of $494.
...read full article on Benzinga
